Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

For five years, insulin ... at $35 per monthly prescription (3 vials or 2 packs of pens) for customers paying with cash. Even Minnesotans with insurance can choose to not use their insurance and pay ...

Today we will run through one way of estimating the intrinsic value of Eli Lilly and Company (NYSE ... A DCF is all about the idea that a dollar in the future is less valuable than a dollar ...

In the kitchen of her South St. Paul home, Abigail Turner prepares the insulin she uses to manage her type 1 diabetes last February. Minnesota announced a final settlement Monday with the last of ...

The settlement resolves the Attorney General’s 2018 lawsuit alleging that Novo Nordisk deceptively priced its insulin ... and pay no more than $35 per month. Like Eli Lilly and Sanofi, Novo ...